Plain-English translation of NCT06970639 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new medication called furmonertinib works better when combined with chemotherapy compared to osimertinib alone in patients with a specific type of lung cancer that has spread to the brain. The trial will enroll about 380 patients across multiple hospitals worldwide. Researchers want to see if this combination approach can help patients live longer and control their disease better.
When lung cancer spreads to the brain, it becomes harder to treat and patients have fewer good options. This medication may be able to reach the brain better than current treatments, and combining it with chemotherapy might work more powerfully than using one drug alone.
You likely qualify if…
You likely don't qualify if…
Participants will be randomly assigned to one of three treatment groups: the new medication plus chemotherapy at one of two dose levels, the standard single medication, or the new medication alone. The trial has two stages—first, about 30 patients will receive treatment to check safety, then about 350 more patients will join the main study. You will have regular visits to your study center for blood tests, scans to measure your tumors, and to receive your medications, with the exact schedule depending on which group you're in.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China